Navigation Links
PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
Date:7/29/2009

INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednesday, August 5, 2009 at 3:30 p.m. Eastern Time.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the Web site at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay will be available at www.pdl.com starting approximately three hours after completion of the webcast.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
2. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
5. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
6. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
7. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
8. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
9. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
10. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
11. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , ... August 09, 2017 , ... ... medicine applications in the clinic is here. The team at Capricor Therapeutics, Inc. ... conditioned medium for clinical studies. , Dr. Travis Antes, head of analytical ...
(Date:8/10/2017)... , ... August 09, 2017 , ... Okyanos Center for ... place at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. ... required. , With oversight from the Ministry of Health’s National Stem Cell Ethics ...
(Date:8/10/2017)... Philadelphia PA and London UK (PRWEB) , ... August 10, 2017 ... ... (SCRS) will host a new educational webinar to demonstrate how Good ... on feasibility, contracts, and site documents. In addition the webinar will discuss the importance ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... news outlet had initiated coverage on Next Group Holdings, Inc. and see's significant ... markets geared toward those that cannot engage in traditional banking services. According to ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):